SOLV (SOLV) fluctuates 148.7% in 24 hours: abnormal surge in trading volume triggers price pump
Bitget Pulse2026/04/03 00:59Volatility Brief
In the past 24 hours, the price of SOLV rebounded from a low of $0.0038 to a high of $0.00945 and is currently quoted at $0.00466, marking a fluctuation amplitude of 148.7%. Trading volume expanded significantly, with CoinGecko data showing a 24-hour trading volume of over $269 million, while CoinMarketCap reports $337 million, both reflecting a substantial increase over typical levels.
Brief Analysis of Causes for the Price Movement
- Abnormal surge in trading volume: Several X posts within 24 hours reported SOLV experiencing anomalous buying activities ranging from 5.7x to 20.6x, driving a short-term price spike; Binance spot and futures trading volume also surged simultaneously.
- No clear catalyst event: Solv Protocol did not release any official announcements in the past 24 hours, nor were there any major news events, significant on-chain whale transfers, or notable DeFi activities recorded.
Market Outlook and Perspectives
The market has listed SOLV as one of the top gainers in the past 24 hours (with gains exceeding 50%-160%). With high volatility and active trading, the mainstream sentiment leans towards speculative Bitcoin DeFi narrative-driven moves. However, analysts warn of short-term correction risks, with the possibility of a 30% drop before a longer-term recovery.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring and is for informational purposes only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
